Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AKT1 E17K

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

AKT1 E17K	Triple Negative Breast Cancer	AKT1 E17K	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
AKT1 E17K	Salivary Gland Cancer	AKT1 E17K	Salivary Gland Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Melanoma	AKT1 E17K	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Colorectal Cancer	AKT1 E17K	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
AKT1 E17K	Estrogen Receptor Positive Breast Cancer	AKT1 E17K	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Solid Tumor	AKT1 E17K	Solid Tumor	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	palbociclib + ARQ 751 Sensitive: D – Preclinical palbociclib + ARQ 751 Sensitive : D	palbociclib + ARQ 751 Sensitive: D – Preclinical palbociclib + ARQ 751 Sensitive : D
AKT1 E17K	Colorectal Cancer	AKT1 E17K	Colorectal Cancer	trametinib + palbociclib Sensitive: D – Preclinical trametinib + palbociclib Sensitive : D	trametinib + palbociclib Sensitive: D – Preclinical trametinib + palbociclib Sensitive : D